+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07899996

Evaluating HB0056 Injection for Adults with Moderate to Severe Asthma Randomized, Double-Blind, Placebo-Controlled Study of Safety and Effectiveness

Led by Shanghai Huaota Biopharmaceutical Co., Ltd. · Updated on 2026-10-28

160

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug HB0056 for treating adults with moderate to severe asthma. This clinical trial aims to find out if HB0056 reduces the need for rescue inhalers and to assess the safety of this medication. The study includes adults aged 18 to 75 years with a history of asthma and ongoing treatment with inhaled corticosteroids and other asthma control drugs. The study has two parts Part I tests different doses of HB0056 compared to a placebo in a randomized, double-blind design to evaluate safety, drug behavior in the body, immune response, and early signs of effectiveness. Part II further explores the best dosing schedules of HB0056 for moderate to severe asthma and continues safety monitoring. Participants receive HB0056 or placebo injections either every two or four weeks. Participants will keep a diary to record symptoms and rescue inhaler use while attending regular visits for lung function tests, asthma control questionnaires, and monitoring for side effects. The study measures lung function changes, asthma exacerbations, quality of life, and immune responses over periods up to 56 weeks. Safety and antibody development are closely observed throughout the trial.

CONDITIONS

Brief Title

A Study of HB0056 in Adult Participants With Moderate to Severe Asthma

Research Team

J

Jingjing Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here